← Back to blog

ObesityWeek 2026: CagriSema, EloraTZP and Retatrutide Data, Explained

ObesityWeek 2026 runs November 14 to 17, and the first announcements are in. Two caveats before the numbers. Most of what follows comes from company press releases about trials, not independent analysis. And apart from Zepbound and Foundayo, the drugs below are investigational, so none of this is something you can get from a pharmacy today.

CagriSema at lower doses (REDEFINE 9)

Novo Nordisk reported results from REDEFINE 9, the first phase 3 trial to test CagriSema below its 2.4 mg / 2.4 mg top dose, presented at the meeting and published in The Lancet Diabetes & Endocrinology. At 68 weeks:

  • 1.7 mg / 1.7 mg: 20.7% average weight loss
  • 1.0 mg / 1.0 mg: 21.0% average weight loss
  • Placebo: 2.0%

Those figures assume everyone stayed on treatment. A second measure that counts people who stopped early gave 19.4% and 18.6% against 4.6% for placebo. Waist circumference fell by about 17 cm on both doses versus 3.6 cm on placebo. The trial was not designed to compare the two doses with each other. Novo also presented a post hoc analysis of an earlier trial in which people who responded early lost about 25% on average.

The announcement focuses on efficacy, so how lower doses compare on side effects is the question to watch. CagriSema remains unapproved in the US. Our earlier decision watch post covers the review timeline.

EloraTZP: eloralintide plus tirzepatide

Lilly presented Phase 2 data on EloraTZP, an investigational combination of the amylin drug eloralintide and tirzepatide, in adults with obesity or overweight and type 2 diabetes. At 48 weeks, Lilly reported:

  • Weight loss of up to 54.1 pounds on average (23.3%) from an average starting weight of 232.4 pounds
  • Up to 60% of participants no longer met the BMI criteria for obesity
  • A1C down by up to 2.9 percentage points, with up to 77% reaching normal blood sugar

In separate patient-reported data, people on eloralintide reported less food noise, fewer cravings and lower alcohol consumption. For background on why amylin is drawing so much interest, see The Amylin Era.

Retatrutide beyond the scale

Lilly also presented retatrutide results in two conditions linked to obesity:

  • Sleep apnea: In TRIUMPH-1, breathing disruptions fell by up to 36.1 events per hour (60.6%) at 80 weeks in adults with moderate-to-severe sleep apnea. In TRIUMPH-2, which enrolled people who also had type 2 diabetes, the drop was up to 28.4 events per hour (48.1%).
  • Knee osteoarthritis pain: Pain scores fell by up to 73.1% at 80 weeks in TRIUMPH-1 and up to 75.8% at 68 weeks in TRIUMPH-4.

Lilly has said it plans to file for approval in the first quarter of 2027. See our pipeline update for the timeline.

How to read these results

Compare across trials with caution. The populations, the dose levels and the way results are calculated all differ, so a bigger number in one press release does not mean one drug beats another. Phase 2 results in particular often shrink or change in larger trials. The more useful takeaway is the direction of travel: the next generation is being measured on sleep apnea, joint pain, blood sugar and food noise, not only on pounds lost.

This article summarizes company announcements and public reporting for general information and is not medical advice. Content was rephrased for compliance. Investigational drugs are not available outside clinical trials; discuss options with your provider.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment protocol.